ACTUATE THERAPEUTICS, INC. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
On 2026-10-28, Actuate Therapeutics (market cap ~$42.1M) received notice of failure to satisfy continued listing standards. Item 3.01 indicates the company faces delisting or transfer of listing. No specific non-compliance details, financial metrics, counterparty information, or remediation timeline are disclosed in the filing header.
Why this rating
Delisting threat is business-critical for small-cap biotech; jeopardizes capital access, credibility, and stock liquidity—core survival risk for $42M company.
Extracted items
Price action (we called it negative)
before filing · preread $0.34 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.